Hi TheDollerLama. If this quote you posted from the newsletter is accurate and turns out to be true, there surely there must be a re-rating of PRR's share price. Up until now it has been valued on Ovarian cancer alone...but if they can at least show it is possible to expand CVac's potential applications, then it will attract a lot of attention IMO
"We will also release immune monitoring data from seven patients in the CAN-003 trial. By using a technique called Intracellular Cytokine Staining (ICS), we can evaluate if CVac induces a mucin-1 specific c T-cell response. Positive data from ICS would give us the confidence to test CVac in other cancer indications and expand CVac’s potential applications"
Hi TheDollerLama. If this quote you posted from the newsletter...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.010(2.50%) |
Mkt cap ! $566.5M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.5¢ | 38.5¢ | $997.5K | 2.559M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 85852 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 75389 | 4 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |